title: Endothelial apoptosis decrease following tadalafil administration in patients with arterial ED does not last after its discontinuation.
abstract: Although it is well known that phosphodiesterase V inhibitors, used to treat patients with ED, can improve the endothelial dysfunction in organic vascular forms, few studies have explored the duration of their effect on the endothelium after discontinuation. Therefore, the purpose of this study was to evaluate the serum concentrations of apoptotic endothelial microparticles (EMPa), selected as a marker of endothelial damage, in patients with arterial ED at baseline, during tadalafil administration and 3 and 6 months after its discontinuation. In all, 50 patients with arterial ED were evaluated at baseline and 1 week after administration of tadalafil 5 mg once daily for 90 days. Clinical (International Index of Erectile Function-5 score), instrumental (dynamic penile echo color Doppler) and flow-cytometric (serum EMPa concentrations) analyses were performed before (T0) and 1 week (T1), 3 months (T2) and 6 months (T3) after tadalafil discontinuation. The events CD45(neg)/CD144(pos)/annexinV(pos) were defined as EMPa. At T0, patients with arterial ED had serum EMPa concentration significantly higher than 20 healthy men (controls). At T1, patients with arterial ED showed a serum EMPa concentration significantly lower than T0. The significant difference was maintained, though reduced, at T2 and completely lost at T3. In conclusion, the administration of tadalafil decreased serum EMPa concentration in patients with arterial ED. This positive effect on the endothelial dysfunction disappeared 6 months after tadalafil discontinuation.
authors.affiliation: Section of Endocrinology, Andrology and Internal Medicine, Master in Andrological, Human Reproduction and Biotechnology Sciences, Department of Internal Medicine and Systemic Diseases, University of Catania, Catania, Italy. sandrolavignera@email.it
authors.forename: S
authors.initials: S
authors.lastname: La Vignera
authors.forename: R A
authors.initials: RA
authors.lastname: Condorelli
authors.forename: E
authors.initials: E
authors.lastname: Vicari
authors.forename: R
authors.initials: R
authors.lastname: D'Agata
authors.forename: A E
authors.initials: AE
authors.lastname: Calogero
mesh_terms: D017209:Apoptosis / Q000187:drug effects*; D002243:Carbolines / Q000494:pharmacology / Q000627:therapeutic use*; D055252:Cell-Derived Microparticles / Q000378:metabolism*; D004730:Endothelium, Vascular / Q000187:drug effects*; D007172:Erectile Dysfunction / Q000188:drug therapy*; D005434:Flow Cytometry; D006801:Humans; D008297:Male; D008875:Middle Aged; D058986:Phosphodiesterase 5 Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000068581:Tadalafil; D013997:Time Factors
chemical_list: D002243:Carbolines; D058986:Phosphodiesterase 5 Inhibitors; D000068581:Tadalafil